Autopsy report · NCT01412515

A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma

“results from interim analysis conducted to study interruption”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 years 2 months after it had already started.
• Ran for about 2 years 11 months before it stopped.
• 11 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Sponsor type

Government (non-US federal)

Conditions

Kaposi Sarcoma

Interventions

everolimus

Participants

11

Sites

1

Countries

France

Trials that died the same way

• Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics
  “study paused for interim analysis” (85% match in meaning)
• RCT of Mobile Apps & FitBit v. Usual Care
  “Study is paused for interim analysis.” (84% match in meaning)
• A Comparison of Surgical Preparations and Wound Infection Rates for Elective Cesarean Sections
  “Study was stopped following interim analysis.” (74% match in meaning)
• Effect of Enzymes on Dental Biofilm Accumulation in Healthy Individuals
  “The study was terminated after interim data analysis” (70% match in meaning)
• Verapamil vs Steroid to Prevent Keloid Recurrence
  “Objective of study achieved after interim analysis.” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.